Epithelial-mesenchymal transition‑associated microRNAs in colorectal cancer and drug-targeted therapies (Review)
- Authors:
- Danjuan Jin
- Yantian Fang
- Zhengyang Li
- Zongyou Chen
- Jianbin Xiang
-
Affiliations: Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China - Published online on: December 1, 2014 https://doi.org/10.3892/or.2014.3638
- Pages: 515-525
This article is mentioned in:
Abstract
 |
 |
 |
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer Statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Croce CM and Iorio MV: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar | |
|
Jeff JH and Yang J: Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013. View Article : Google Scholar | |
|
Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal-transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Jang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar | |
|
Pino MS, Kikuchi H, Zeng M, et al: Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology. 138:1406–1417. 2010. View Article : Google Scholar : | |
|
Savagner P: The epithelial-mesenchymal transition phenomenon. Ann Oncol. 21:89–92. 2010. View Article : Google Scholar | |
|
Bonnomet A, Brysse A, Tachsidis A, et al: Epithelial-tomesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia. 15:261–273. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lun H and Shourong S: EMT phenomenon and related microRNAs in the malignant progression of tumor. Chin Oncol. 21:725–730. 2011. | |
|
Cavallaro U, Schaffhauser B and Christofori G: Cadherins and the tumour progression: is it all in a switch? Cancer Lett. 176:123–128. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Saito Y, Takazawa H, Uzawa K, et al: Reduced expression of E-cadherin in oral squamous cell carcinoma: Relationship with DNA methylation of 5′ CpG island. Int J Oncol. 12:293–298. 1998.PubMed/NCBI | |
|
Lester RD, Jo M, Montel V, et al: uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 178:425–436. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Berx G and Van Roy F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 3:289–293. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Canel M, Serrels A, Frame MC, et al: E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Derycke LD and Bracke ME: N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signaling. Int J Dev Biol. 48:463–476. 2004. View Article : Google Scholar | |
|
Hazan RB, Qiao R, Keren R, et al: Cadherin switch in tumor progression. Ann NY Acad Sci. 1014:155–163. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rosivatz E, Becker I, Bamba M, et al: Neoexpression of N-cadherin in E-cadherin positive colon cancers. Int J Cancer. 111:711–719. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Colomiere M, Findlay J, Ackland L and Ahmed N: Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6betal integrin. Int J Biochem Cell Biol. 41:1034–1045. 2009. View Article : Google Scholar | |
|
Vora HH, Patel NA, Rajvik KN, et al: Cytokerain and vimentin expression in breast cancer. Int J Biol Markers. 24:38–46. 2009.PubMed/NCBI | |
|
Shirahata A, Sakata M, Sakuraba K, et al: Vimentin methylation as a marker or advanced colorectal carcinoma. Anticancer Res. 29:279–281. 2009.PubMed/NCBI | |
|
Wei J, Xu G, Wu M, et al: Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 28:327–334. 2008.PubMed/NCBI | |
|
Pankov R and Yamada KM: Fibronectin at a glance. J Cell Science. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Birchler MT, Milisavlijevic D, Pfaltz M, et al: Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope. 113:1231–1237. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cano A, Perez-Moreno MA, Rodrigo I, et al: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 12:76–83. 2000. View Article : Google Scholar | |
|
Hajra KM, Chen DY and Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62:1613–1618. 2002.PubMed/NCBI | |
|
Eger A, Aigner K, Sonderegger S, et al: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 24:2375–2385. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kim T, Veronese A, Pichiorri F, et al: p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Fang X, Cai Y, Liu J, et al: Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene. 30:4707–4720. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Casas E, Kim J, Bendesky A, et al: Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 71:245–254. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nusse R and Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 31:99–109. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Kurayoshi M, Oue N, Yamamoto H, et al: Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 66:10439–10448. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Dissanayake SK, Wade M, Johnson CE, et al: The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 282:17259–17271. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Huelsken J and Behrens J: The Wnt signaling pathway. J Cell Sci. 115:3977–3978. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
King TD, Zhang W, Suto MJ, et al: Frizzled7 as an emerging target for cancer therapy. Cell Signal. 24:846–851. 2012. View Article : Google Scholar : | |
|
MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Deka J, Wiedemann N, Anderle P, et al: Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res. 70:6619–6628. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hlubek F, Spaderna S, Schmalhofer O, et al: Wnt/FZD signaling and colorectal cancer morphogenesis. Front Biosci. 12:458–470. 2007. View Article : Google Scholar | |
|
Beiter K, Hiendlmeyer E, Brabletz T, et al: Beta-catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene. 24:8200–8204. 2005.PubMed/NCBI | |
|
Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar | |
|
Watanabe Y, Itoh S, Goto T, et al: TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling. Mol Cell. 37:123–134. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tsukazaki T, Chiang TA, Davison AF, et al: SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 95:779–791. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Müller N, Reinacher-Schick A, Baldus S, et al: SMAD4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells. Oncogene. 21:6049–6058. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Mu Y, Gudey SK and Landström M: Non-SMAD signaling pathways. Cell Tissue Res. 347:11–20. 2012. View Article : Google Scholar | |
|
Hong M, Wilkes MC, Penheiter SG, et al: Non-Smad transforming growth factor-β signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem. 286:17841–17850. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kang JS, Liu C and Derynck R: New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol. 19:385–394. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hartsough MT and Mulder KM: Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem. 270:7117–7124. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Park SS, Eom YW, Kim EH, et al: Involvement of c-Src kinase in the regulation of TGF-beta1-induced apoptosis. Oncogene. 23:6272–6281. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yu L, Hebert MC and Zhang YE: TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21:3749–3759. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Timmerman LA, Grego Bessa J, Raya A, et al: Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 18:99–115. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Leong KG, Niessen K, Kulic I, et al: Jagged l-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 204:2935–2948. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sahlgren C, Gustafsson MV, Jin S, et al: Notch signaling mediates hypoxia induced tumor cell migration and invasion. Proc Natl Acad Sci USA. 105:6392–6397. 2008. View Article : Google Scholar | |
|
Veenendaal LM, Kranenburg O, Smakman N, et al: Differential Notch and TGFbeta signaling in primary colorectal tumors and their corresponding metastases. Cell Oncol. 30:1–11. 2008.PubMed/NCBI | |
|
Murone M, Rosenthal A and de Sauvage FJ: Sonic hedgehog signaling by the patched-smoothened receptor complex. Curr Biol. 9:76–84. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Chen JS, Huang XH, Wang Q, et al: Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis. 34:10–19. 2013. View Article : Google Scholar | |
|
Zhang H, Berezov A, Wang Q, et al: ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 117:2051–2058. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Oda K, Matsuoka Y, Funahashi A, et al: A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 1:2005.00102005. View Article : Google Scholar | |
|
Wu L, Fan J and Belasco JG: MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA. 103:4034–4039. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wienholds E, Koudijs MJ, van Eeden FJ, et al: The microRNA-producing enzyme Dicer1 is essencial for zebrafish development. Nat Genet. 35:217–218. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Pasquinelli AE, Reinhart BJ, Slack F, et al: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 408:86–89. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Y, Shi C, Manduchi E, et al: MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci USA. 107:13450–13455. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai KW, Wu CW, Hu LY, et al: Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 129:2600–2610. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yan W, Song G-X and Li Q: Advances in understanding the relationship between microRNAs and colorectal cancer. World Chin J Digestol. 19:3426–3431. 2011. | |
|
Ng EK, Chong WW, Jin H, et al: Differential expression of microRNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut. 58:1375–1381. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hurteau GJ, Carlson JA, Spivack SD, et al: Overexpression of the microRNA has-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 67:7972–7976. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gregory PA, Bert AG, Paterson EL, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Park SM, Gaur AB, Lengyel E, et al: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Burk U, Schubert J, Wellner U, et al: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shell S, Park SM, Radjabi AR, et al: Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA. 104:11400–11405. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Wang C, Chen Z, et al: MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma lines. Biochem J. 440:23–31. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Castilla MA, Moreno-Bueno G, Romero-Perez L, et al: Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 233:72–80. 2011. View Article : Google Scholar | |
|
Li QQ, Chen ZQ, Cao XX, et al: Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ. 18:16–25. 2011. View Article : Google Scholar : | |
|
Meng Z, Fu X, Chen X, et al: miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology. 52:2148–2157. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ma L, Teruya-Feldstein J and Weinberg RA: Tumor invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kong W, Yang H, He L, et al: MicroRNA155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 28:6773–6784. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cottonham CL, Kaneko S and Xu L: miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem. 285:35293–35302. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Asangani IA, Rasheed SA, Nikolova DA, et al: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar | |
|
Wang P, Zho F, Zheng X, et al: microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 69:8157–8165. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ma L, Young J, Prabhala H, et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 12:247–256. 2010.PubMed/NCBI | |
|
Vetter G, Saumet A, Moes M, et al: miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene. 29:4436–4448. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Castilla MA, Moreno-Bueno G, Romero-Pérez L, et al: Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 223:72–80. 2011. View Article : Google Scholar | |
|
De Krijger I, Mekenkamp LJ, Punt CJ and Nagtegaal ID: MicroRNAs in colorectal cancer metastasis. J Pathol. 224:438–447. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M and Chen H: The role of microRNAs in colorectal cancer. J Genet Genomics. 37:347–358. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Spaderna S, Schmalhofer O, Hlubek F, et al: A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 131:830–840. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Spaderna S, Schmalhofer O, Wahlbuhl M, et al: The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 68:537–544. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Korpal M, Lee ES, Hu G and Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Brabletz S and Brabletz T: The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fujita S, Ito T, Mizutani T, et al: miR-21 gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol. 378:492–504. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ferraro A, Kontos CK, Boni T, et al: Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGB4-PDCD4) as predictor of metastatic tumor potential. Epigenetics. 9:129–141. 2014. View Article : Google Scholar : | |
|
Bommer GT, Gerin I, Feng Y, et al: p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chang TC, Wentzel EA, Kent OA, et al: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yamakuchi M, Ferlito M and Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Siemens H, Jackstadt R, Hünten S, et al: miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 10:4256–4271. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim NH, Kim HS, Li XY, et al: A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol. 195:417–433. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rokavec M, Oner MG, Li H, et al: IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 124:1853–1867. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bandi N, Zbinden S, Gugger M, et al: miR-15a and miR16 are implicated in cell cycle regulation a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69:5553–5559. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jackstadt R, Röh S, Neumann J, et al: AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med. 210:1331–1350. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shi L, Jackstadt R, Siemens H, et al: p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 74:532–542. 2014. View Article : Google Scholar | |
|
Dihlmann S, Siermann A and von Knebel Doeberitz M: The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 20:645–653. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Boon EM, Keller JJ, Wormhoudt TA, et al: Sulindac targets nuclear beta-catenin accumulation and Wnt signaling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 90:224–229. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Linna L and Shoujun Y: Wnt/β-catenin signaling pathway and strategy of originating and treatment in colorectal cancer. World Chin J Digestol. 14:201–206. 2006. | |
|
Zhou L, An N, Haydon RC, et al: Tyrosine kinase inhibitor STI-571/Gleevec down-regulatates the beta-catenin signaling activity. Cancer Lett. 193:161–170. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Green DW, Roh H, Pippin JA and Drebin JA: Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res. 101:16–20. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki H, Watkins DN, Jair KW, et al: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 36:417–422. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Katz LH, Li Y, Chen JS, et al: Targeting TGF-β signaling in cancer. Expert Opin Ther Targets. 17:743–760. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, et al: TGF-beta signaling in colon carcinogenesis. Cancer Lett. 314:1–7. 2012. View Article : Google Scholar | |
|
Melisi D, Ishiyama S, Sclabas GM, et al: LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancteatic cancer metastasis. Mol Cancer Ther. 7:829–840. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Korpal M, Yan J, Lu X, et al: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 15:960–966. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Halder SK, Zhang S and Datta PK: Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett. 277:114–120. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Connolly EC, Freimuth J and Akhurst RJ: Comlexities of TGF-β targeted cancer therapy. Int J Biol Sci. 8:964–978. 2012. View Article : Google Scholar | |
|
Zhao BM and Hoffmann FM: Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell. 17:3819–3831. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Espinoza I, Pochampally R, Xing F, et al: Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther. 6:1249–1259. 2013.PubMed/NCBI | |
|
Yan M and Plowman GD: Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13:7243–7246. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi I, Takatori S, Urano Y, et al: Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene. 31:787–798. 2012. View Article : Google Scholar | |
|
Funahashi Y, Hernandez SL, Das I, et al: A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 68:4727–4735. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tammam J, Ware C, Efferson C, et al: Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumor effects in mouse models of T-cell leukaemia. Br J Pharmacol. 158:1183–1195. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fouladi M, Stewart CF, Olson J, et al: Phase I trial of MK_0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 29:3529–3534. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Moellering RE, Cornejo M, Davis TN, et al: Direct inhibition of the NOTCH transcription factor complex. Nature. 462:182–188. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou W, Kallifatidis G, Baumann B, et al: Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 37:551–561. 2010.PubMed/NCBI | |
|
Kallifatidis G, Labsch S, Rausch V, et al: Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 19:188–195. 2011. View Article : Google Scholar : | |
|
Espinozal I and Miele L: Notch inhibitors for cancer treatment. Pharmacol Ther. 139:95–110. 2013. View Article : Google Scholar | |
|
Kelleher FC: Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis. 32:445–451. 2011. View Article : Google Scholar | |
|
Feldmann G, Dhara S, Fendrich V, et al: Blockade of Hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67:2187–2196. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Agyeman A, Mazumdar T and Houghton JA: Regulation of DNA damage following termination of Hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer. Oncotarget. 3:854–868. 2012.PubMed/NCBI | |
|
Stecca B, Ruiz I and Altaba A: Context-dependent regulation of the GLI code in cancer by Hedgehog and non-Hedgehog signals. J Mol Cell Biol. 2:84–95. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lauth M and Toftqard R: Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle. 6:2458–2463. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hegan S, Orr MC and Doyle B: Targeted therapies in colorectal cancer - an integrative view by PPPM. EPMA J. 4:32013. View Article : Google Scholar | |
|
Ebi H, Corcoran RB, Singh A, et al: Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 121:4311–4321. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 25:1658–1664. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Jonker DJ, O’Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Van Cutsem E, Köhne CH, Lang I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Heinemann V, von Weikersthal LF, Decker T, et al: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol. 31:LBA3506 ASCO Annual Meeting. 2013. | |
|
Dassow H and Aigner A: MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapy. Curr Pharm Des. 19:1242–1252. 2013.PubMed/NCBI | |
|
Weiler J, Hunziker J and Hall J: Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease. Gene Ther. 13:496–502. 2006. View Article : Google Scholar | |
|
Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z, Vilkaitis G, Yu B, et al: Approaches for studying MicroRNA and small interfering RNA methylation in vitro and in vivo. Methods Enzymol. 427:139–154. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ørom UA, Kauppinen S and Lund AH: LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 10:137–141. 2006. View Article : Google Scholar | |
|
Vester B and Wengel J: LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry. 43:13233–13241. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Krützfeldt J, Rajewsky N, Braich R, et al: Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 438:685–689. 2005. View Article : Google Scholar | |
|
Si ML, Zhu S, Wu H, et al: miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007. View Article : Google Scholar | |
|
Corsten MF, Miranda R, Kasmieh R, et al: MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 67:8994–9000. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Meng F, Henson R, Lang M, et al: Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ebert MS, Neilson JR and Sharp PA: MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 4:721–726. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ebert MS and Sharp PA: MicroRNA sponges: progress and possibilities. RNA. 16:2043–2050. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Valastyan S, Reinhardt F, Benaich N, et al: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao J, Yang B, Lin H, et al: Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol. 212:285–292. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gumireddy K, Young DD, Xiong X, et al: Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl. 47:7482–7484. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lennox KA and Behlke MA: Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 18:1111–1120. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yang N, Kaur S, Volinia S, et al: MicroRNA microarray identifles Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 68:10307–10314. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar MS, Erkeland SJ, Pester RE, et al: Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 105:3903–3908. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bonci D, Coppola V, Musumeci M, et al: The miR-15a-miR-16–1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 14:1271–1277. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wiggins JF, Ruffino L, Kelnar K, et al: Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Zhu X, Zhang X, et al: Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 18:1650–1656. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
La Rocca G, Badin M, Shi B, et al: Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-1 receptor signaling pathway. J Cell Physiol. 220:485–491. 2009. View Article : Google Scholar : PubMed/NCBI |
